Status | Study |
Not yet recruiting |
Study Name: Copanlisib and Gemcitabine in Relapsed/Refractory PTCL Condition: Mature T-Cell and NK-Cell Neoplasm Date: 2017-02-10 Interventions: Drug: Copanlisib |
Recruiting |
Study Name: Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas Condition: T-cell Non-Hodgkin Lymphoma Lymphoma, Extranodal NK-T-Cell Date: 2016-08-04 Interventions: Drug: Busulfan intravenous, 3. |
Terminated |
Study Name: Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma Condition: Extranodal NK-T-CELL LYMPHOMA Date: 2016-06-09 Interventions: Drug: GIFOX-Bortezomib GIFOX-B |
Recruiting |
Study Name: MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma Condition: Extranodal NK/T-cell Lymphoma, Nasal Type Date: 2015-11-28 Interventions: Drug: Methotrexate 1g/m2/d IV |
Active, not recruiting |
Study Name: Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma Condition: Nasal Type Extranodal NK/T-Cell Lymphoma Date: 2015-11-22 Interventions: Drug: Pegaspargase Drug: Methotrexate |
Completed |
Study Name: International Extranodal NK/T-cell Lymphoma Project Condition: Extranodal NK/T-cell Lymphoma, Nasal Type Date: 2015-03-06 |
Recruiting |
Study Name: Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage Condition: Lymphoma, Extranodal NK-T-Cell Date: 2015-02-04 Interventions: Drug: Gemcitabine gemcitabine |
Completed |
Study Name: Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma Condition: Stage I/II Extranodal NK/T-cell Lymphoma Date: 2014-10-23 Interventions: Radiation: Intensity-modulated radiation therapy |
Not yet recruiting |
Study Name: Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX Chemotherapy Condition: Lymphoma, Non-Hodgkin Lymphoma, Extranodal Date: 2014-08-27 Interventions: Radiation: Mild-dose IMRT IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated r |
Active, not recruiting |
Study Name: GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma Condition: Extranodal NK/T-cell Lymphoma, Nasal Type Date: 2013-11-07 Interventions: Drug: High dose of methotrexate |